University Herzentrum Division of Cardiology and Angiology II,University Heart Center Freiburg, Südring 15
Welcome,         Profile    Billing    Logout  
 29 Trials 
30 Trials

   Remove FilterRemove Filter

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Neumann, Franz-Josef
LANDMARK, NCT04275726: Trial: a Randomised Controlled Trial of Myval THV

Recruiting
N/A
768
Europe, RoW
Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site.
Meril Life Sciences Pvt. Ltd.
Aortic Valve Stenosis
03/24
12/33
Kim, Won Seog
NCT01937806: Phase 3 and Extensional Study of Besifovir

Active, not recruiting
3
197
RoW
besifovir 150mg, tenofovir 300mg
IlDong Pharmaceutical Co Ltd
Chronic Hepatitis B
02/16
01/23
NCT05450601: A Study to Evaluate the Efficacy and Safety of HCP2102 in Essential Hypertension Patients

Completed
3
249
RoW
HCP2102-1, HPP2104-1, HCP2102-2, HPP2104-2, RLD2106-1, HPP2103-1, RLD2106-2, HPP2103-2
Hanmi Pharmaceutical Company Limited
Hypertension
12/23
12/23
BRUIN CLL-321, NCT04666038: Study of LOXO-305 Versus Investigator's Choice (IdelaR or BR) in Patients With Previously Treated Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
250
Europe, Canada, Japan, US, RoW
LOXO-305, Pirtobrutinib, Idelalisib, Zydelig, Bendamustine, Treanda, Treakisym, Ribomustin, Levact, Rituximab, Rituxan, MabThera, Truxima
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
08/23
05/27
BRUIN-MCL-321, NCT04662255 / 2020-004553-72: Study of BTK Inhibitor LOXO-305 Versus Approved BTK Inhibitor Drugs in Patients With Mantle Cell Lymphoma (MCL)

Active, not recruiting
3
500
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib, Imbruvica, Acalabrutinib, Calquence, Zanubrutinib, Brukinsa
Loxo Oncology, Inc., Eli Lilly and Company
Lymphoma, Mantle-Cell
12/25
07/26
ECHELON-3, NCT04404283 / 2020-002686-33: Brentuximab Vedotin Plus Lenalidomide and Rituximab for the Treatment of Relapsed/Refractory DLBCL

Hourglass Jan 2023 - Dec 2023 : From:ECHELON-3 trial in combination with brentuximab vedotin and rituximab for r/r DLBCL
Active, not recruiting
3
240
Europe, Canada, US, RoW
Brentuximab vedotin, Rituximab, Lenalidomide, Placebo
Seagen Inc.
Diffuse Large B-cell Lymphoma
05/25
04/27
BRUIN CLL-322, NCT04965493 / 2021-000043-49: A Trial of Pirtobrutinib (LOXO-305) Plus Venetoclax and Rituximab (PVR) Versus Venetoclax and Rituximab (VR) in Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL)

Recruiting
3
600
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Venetoclax, Venclexta, Venclyxto, Rituximab, Rituxan, MabThera, Truxima, Riabni, Ruxience
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma
04/26
01/27
B-Well1, NCT05630807 / 2021-005139-22: Study of Bepirovirsen in Nucleos(t)Ide Analogue-treated Participants With Chronic Hepatitis B (B-Well 1)

Active, not recruiting
3
941
Europe, Canada, Japan, US, RoW
Bepirovirsen, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Chronic Hepatitis B, Hepatitis B, Chronic
11/25
05/26
SYMPHONY-1, NCT04224493 / 2019-003333-42: A Study to Assess the Efficacy, Safety, Pharmacodynamics, and Pharmacokinetics of Tazemetostat in Combination With Lenalidomide Plus Rituximab Versus Placebo in Combination With Lenalidomide Plus Rituximab in Adult Patients at Least 18 Years of Age With Relapsed/Refractory Follicular Lymphoma.

Jan 2023 - Dec 2023: DOR/PFS data from P1b portion of P1b/3 SYMPHONY-1 trial in combination with Revlimid and Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2023 - Dec 2023 : First interim futility data from P3 portion of P1b/3 SYMPHONY-1 trial in combination with Rituxan for relapsed/refractory follicular lymphoma
Hourglass Jan 2022 - Dec 2022 : Completion of enrollment of P3 portion of P1b/3 trial for r/r follicular lymphoma
Checkmark Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
Jun 2022 - Jun 2022: Data from SYMPHONY-1 trial in combination with Rituxan and Revlimid for follicular lymphoma
More
Recruiting
3
612
Europe, Canada, US, RoW
Tazemetostat, EPZ-6438, IPN60200, Placebo oral tablet, Lenalidomide, Rituximab
Epizyme, Inc.
Relapsed/Refractory Follicular Lymphoma, Follicular Lymphoma, Refractory Follicular Lymphoma
03/26
03/29
NCT05067634 / 2020-005344-27: Safety and Efficacy Study of Cenobamate in Pediatric Subjects 2-17 Years of Age with Partial-onset (focal) Seizures

Recruiting
3
140
Europe, US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
05/26
07/26
BRUIN-CLL-314, NCT05254743 / 2021-003206-41: A Study of Pirtobrutinib (LOXO-305) Versus Ibrutinib in Participants With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL)

Active, not recruiting
3
650
Europe, Canada, Japan, US, RoW
Pirtobrutinib, LOXO-305, LY3527727, Ibrutinib
Loxo Oncology, Inc., Eli Lilly and Company
Chronic Lymphocytic Leukemia, Leukemia, Lymphocytic, Leukemia, B-cell, Small Lymphocytic Lymphoma
06/25
01/28
REDIRECT, NCT04101331 / 2019-001003-20: Phase II Study to Assess AFM13 in Patients With R/R CD30-positive T-cell Lymphoma or Transformed Mycosis Fungoides

Completed
2
108
Europe, US, RoW
AFM13
Affimed GmbH
Peripheral T Cell Lymphoma, Transformed Mycosis Fungoides
05/22
01/24
JACKPOT8, NCT04105010: Assessing An Oral Janus Kinase Inhibitor, AZD4205 as Monotherapy in Patients Who Have PTCL

Completed
2
171
US, RoW
AZD4205
Dizal Pharmaceuticals
Relapsed or Refractory Peripheral T Cell Lymphoma
10/23
02/24
DISTINKT, NCT04414163: A Study of IMC-001 in Subjects With Relapsed or Refractory Extranodal NK/T Cell Lymphoma, Nasal Type

Active, not recruiting
2
23
RoW
IMC-001, Not confirm yet
ImmuneOncia Therapeutics Inc.
Extranodal NK/T-cell Lymphoma, Nasal Type, Extranodal NK/T-cell Lymphoma
07/24
02/26
STARLIGHT, NCT06613698: A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 65 Years With Alcohol-related Liver Disease

Not yet recruiting
2
393
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline
Liver Diseases, Alcoholic
12/26
03/27
Lemon-C, NCT04627753: Study of Lenalidomide/Rituximab Maintenance for Transplantation Ineligible Patients With PCNSL.

Recruiting
2
30
RoW
Rituximab, lenalidomide, Truxima Inj, Lenalid
Kim, Seok Jin, Celltrion, Samyang Biopharmaceuticals Corporation
Primary CNS Lymphoma
11/25
11/26
B-UNITED, NCT06537414: A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living With Chronic Hepatitis B (CHB)

Recruiting
2
280
Europe, Canada, Japan, US, RoW
Daplusiran/Tomligisiran Dose Level 1, Daplusiran/Tomligisiran Dose Level 2, Bepirovirsen, Placebo
GlaxoSmithKline
Chronic Hepatitis B Virus Infection, Hepatitis B
10/27
10/27
EPCORE DLBCL-3, NCT05660967 / 2021-005744-29: Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for Diffuse Large B-Cell Lymphoma

Recruiting
2
180
Europe, Japan, US, RoW
Epcoritamab, GEN3013, DuoBody®-CD3×CD20, EPKINLY™, Lenalidomide, Revlimid®
Genmab, AbbVie
Diffuse Large B-Cell Lymphoma
01/26
07/27
NCT04505436: Study to Evaluate Efficacy, Safety and Tolerability of HM15211 in Subjects

Recruiting
2
240
US, RoW
HM15211, Placebo of HM15211
Hanmi Pharmaceutical Company Limited
NASH - Nonalcoholic Steatohepatitis
05/26
11/26
HORIZON, NCT05583344 / 2022-002538-14: Phase 2b Study of GSK4532990 in Adults With NASH

Active, not recruiting
2
271
Europe, Canada, Japan, US, RoW
GSK4532990, Placebo
GlaxoSmithKline, GlaxoSmithKline Research & Development Limited
Nonalcoholic Fatty Liver Disease, Non-alcoholic Fatty Liver Disease
12/25
03/26
ALTAMIRA, NCT05214183: Acalabrutinib and Rituximab in Elderly Patients With Untreated Mantle Cell Lymphoma

Active, not recruiting
2
81
Europe, RoW
Acalabrutinib-rituximab in patients with untreated mantle cell lymphoma
Nordic Lymphoma Group, AstraZeneca
MCL, Mantle Cell Lymphoma
01/27
01/27
NCT03789617: A Multi-center, Single-arm, Open, Phase I/IIa Clinical Trial to Evaluate the Efficacy and Safety of EBViNT Cell (EBV Specific Autologous CD8+ T Cell) in Patients With Treatment Failed Epstein Barr Virus (EBV)-Positive Malignancies

Recruiting
1/2
72
RoW
EBViNT Cell, Eutil autologous blood-derived T lymphocytes
Eutilex
EBV Associated Extranodal NK/T-cell Lymphoma, EBV-Associated GastricCarcinoma or Esophageal AdenoCarcinoma
09/22
12/24
KEYNOTE-877, NCT03674567: Dose Escalation and Expansion Study of FLX475 Monotherapy and in Combination With Pembrolizumab

Active, not recruiting
1/2
323
US, RoW
FLX475, pembrolizumab (KEYTRUDA®)
RAPT Therapeutics, Inc., Merck Sharp & Dohme LLC
Advanced Cancer
09/24
01/25
NCT02580617: A Study to Evaluate the Safety of ALLO-ASC-CD for Treatment of Crohn's Disease

Recruiting
1
9
RoW
ALLO-ASC, ALLO-ASC-CD
Anterogen Co., Ltd.
Crohn's Disease
12/23
12/23
NCT04903314: Dose-Escalation Study of Cenobamate (YKP3089) in Pediatric Subjects with Partial-Onset Seizures

Recruiting
1
24
US, RoW
Xcopri
SK Life Science, Inc.
Partial Epilepsy
10/25
03/26
NCT06699771: Phase 1 to Investigate the Safety, Tolerability, and Efficacy of GCC2005 in Patients With R/R NK and T-cell Malignancies

Not yet recruiting
1
48
RoW
GCC2005, Cyclophosphamide, Fludarabine
GC Cell Corporation, Artiva Biotherapeutics, Inc.
Lymphoma, T-Cell
04/26
08/27
NCT06522815: Updating Deep Learning Algorithms for OSA Monitoring

Recruiting
N/A
107
RoW
CART-I plus, Polysomnography
Sky Labs, Gangnam Severance Hospital
Obstructive Sleep Apnea, Obstructive Sleep Apnea-hypopnea
04/25
07/25
LANDMARK, NCT04275726: Trial: a Randomised Controlled Trial of Myval THV

Recruiting
N/A
768
Europe, RoW
Myval THV Series, Myval/Myval Inception THVs or any subsequent advanced version commercially available at the study site., Contemporary Valves (Sapien THV Series and Evolut THV Series), Sapien THV Series (Sapien 3/Sapien 3 Ultra THVs) and Evolut THV Series (Evolut R/Evolut PRO THVs ) or any subsequent advanced version commercially available at the study site.
Meril Life Sciences Pvt. Ltd.
Aortic Valve Stenosis
03/24
12/33
NCT05124912: REMASTer: REcurrent Brain Metastases After SRS Trial

Recruiting
N/A
261
US
Radiation Therapy, Steroid Therapy, Laser Interstitial Thermal Therapy
Monteris Medical
Brain Metastases, Radiation Necrosis, Recurrent Tumor, Recurrent Metastases
12/26
10/28
NCT03183661: A Follow-up Study to Evaluate the Safety of ALLO-ASC-CD in ALLO-ASC-CD-101 Clinical Trial

Recruiting
N/A
9
RoW
ALLO-ASC-CD, Allogenic adipose-derived mesenchymal stem cell
Anterogen Co., Ltd.
Crohn Disease
12/26
12/26

Download Options